AIMEE DINWOODIE: Open Payments
NPI 1164761672 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 56 payments from 15 companies in 2025. Trend: 2023 $1,551 · 2024 $1,711 · 2025 $962
Food & beverage: $962
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $346 |
| Madrigal Pharmaceuticals | 4 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Aimmune Therapeutics, Inc. | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Janssen Biotech, Inc. | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 5 | $41 |
| Gilead Sciences, Inc. | 2 | $33 |
| GENZYME CORPORATION | 1 | $29 |
| Blueprint Medicines Corporation | 1 | $27 |
Products named: RINVOQ, REZDIFFRA, SKYRIZI, DUPIXENT, CREON, ENTYVIO, TREMFYA, VOQUEZNA.
Industry payments across FL — which companies pay providers there.
